title: Safety and immunogenicity of hepatitis B vaccine ButaNG in adults
abstract: Recombinant yeast-derived hepatitis B vaccine manufactured by Instituto Butantan was administered in two groups of adult volunteers (I, II) following two different schedules of immunization. In the first trial (10 &mgr;g doses and 0, 1, 3 months vaccination schedule) 106 individuals completed the full immunization program. The results of seroconversion by age group varied from 70 to 100% and the GMT from 46.5 to 124.9 mIU mL-1. In the second trial with 68 individuals (for dosage comparison and 0, 1, 6 months vaccination schedule) indicated that the vaccine formulated in 20 &mgr;g was more effective than in 10 &mgr;g. The adverse reactions observed in the vaccinees were less frequent than the ones previously found since the introduction of similar vaccines.
authors.affiliation: Centro de Biotecnologia, Instituto Butantan, Sao Paulo, SP, 05503-900, Brazil.
authors.initials: LM
authors.lastname: Ioshimoto
authors.initials: ML
authors.lastname: Rissato
authors.initials: VS
authors.lastname: Bonilha
authors.initials: C
authors.lastname: Miyaki
authors.initials: I
authors.lastname: Raw
authors.initials: N
authors.lastname: Granovski